Targeted Drug Trio for Colorectal Cancer with BRAF Mutations - Cancer Currents Blog

Having trouble viewing this email? View it as a Web page.

You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below.     Targeted Drug Trio Improves Survival in Colorectal Cancer with BRAF Mutations 11/13/2019 For people with colorectal cancer with a specific mutation in the BRAF gene, a treatment regimen of three targeted drugs can improve how long they live without increasing their risk of serious side effects, results from a new clinical trial show.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp       Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892